Briacell Therapeutics Has Dosed The First Patient In Its Phase 1/2 Study To Evaluate The Safety And Efficacy Of Bria-OTS, Briacell's Personalized Next Generation Immunotherapy

Benzinga · Nov 21 20:51

The study will investigate Bria-OTS alone and in combination with immune check point inhibitor tislelizumab (manufactured and supplied by BeiGene) for the treatment of metastatic breast cancer.

Bria-OTS is an enhanced form of Bria-IMT, currently in pivotal Phase 3 study for metastatic breast cancer.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Briacell Therapeutics Has Dosed The First Patient In Its Phase 1/2 Study To Evaluate The Safety And Efficacy Of Bria-OTS, Briacell's Personalized Next Generation Immunotherapy

Risk Disclaimer